Diffuse Fatty Infiltration of the Liver

Treatment for Fatty Infiltration of the Liver Your liver cells normally contain a small
amount of stored fat. Nonalcoholic fatty liver disease (NAFLD) describes
the abnormal accumulation of fat in liver cells not caused by excessive alcohol consumption
or another liver condition, such hepatitis B or C. The two types of NAFLD include nonalcoholic
fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH). These conditions differ in that there is no
inflammation or liver cell damage with NAFL but both are present with NASH. Risk factors for NAFLD include type 2 diabetes,
prediabetes, high blood pressure, overweight or obesity, and abnormal blood fat levels. Treatment centers primarily on lifestyle modification
to improve underlying risk factors to reduce the likelihood of developing liver scarring
and cirrhosis. Weight Reduction
Weight reduction is a cornerstone of NAFLD treatment. A pooled analysis of 8 studies published in
April 2012 in the journal Diabetologia reported that just a 7 percent reduction in body weight
resulted in decreased liver cell fat and liver disease improvement. The authors noted that improvements increased
in parallel with the percentage of weight reduction. Reducing your caloric intake helps with NAFLD
because it mobilizes the stored fat in your liver cells. In addition to liver disease improvements,
weight reduction in these studies was associated with improvements in markers for heart disease
risk, such as levels of blood fats. This is important because people with NAFLD
are at increased risk for heart disease. Approach
According to January 2018 practice guidance from the American Association for the Study
of Liver Diseases (AASLD), there is insufficient evidence to recommend a specific weight-reduction
diet for the treatment of NAFLD. However, the guidance states that data suggest
decreasing caloric intake by at least 30 percent or by approximately 750 to 1,000 calories
daily results in reduced liver cell fat. Physical Activity
The AASLD guidance for NAFLD management states that the combination of a reduced-calorie
diet and moderate-intensity exercise provides the greatest opportunity for sustained weight
reduction. This is likely because exercise helps increase
your metabolic rate and burns calories. There is also some evidence that exercise
might reduce liver cell fat even with minimal to no associated weight loss, as reported
in a July 2012 Journal of Hepatology article. Medications and Supplements Pioglitazone
As of January 2018, AASLD guidance includes only one prescription medication for consideration
to specifically treat NASH. Pioglitazone (Actos) was developed as a type
2 diabetes medication but has been shown to improve liver inflammation and other indicators
of liver damage in people with NASH. AASLD states this medication may be used to
treat biopsy-proven NASH in people with or without type 2 diabetes after a discussion
of potential risks and benefits. Potential risks include weight gain and bone
loss in women. AASLD does not currently recommend pioglitazone
for people with NAFL. Vitamin E
An excess of free radicals — chemicals that can lead to cellular injury when present in
abnormally high concentrations — is thought to contribute to liver damage in people with
NASH. Vitamin E is a potent antioxidant, a substance
that neutralizes free radicals. Other Considerations Visit the website. Click Below

Leave a Reply

Your email address will not be published. Required fields are marked *